title: Antithrombotic treatment in atrial fibrillation.
abstract: Atrial fibrillation (AF) is the most common sustained arrhythmia, that substantially increases morbidity and mortality. AF is gaining in clinical and economic importance, with stroke and thromboembolism being major complications. In this article, the evidence for AF treatment trial of antithrombotic therapy is reviewed. Stroke risk stratification of patients with AF is discussed, and practical recommendations for thromboprophylaxis are presented.
authors.affiliation: University Department of Medicine, City Hospital, Birmingham, UK. g.y.h.lip@bham.ac.uk
authors.forename: G Y H
authors.initials: GY
authors.lastname: Lip
authors.forename: C J
authors.initials: CJ
authors.lastname: Boos
mesh_terms: D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000209:etiology
chemical_list: D005343:Fibrinolytic Agents